Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Videos [1603]

Optimisation of supportive, palliative and end of life care

Dr Zipporah Ali - Africa Organisation for Research & Training in Cancer, Kenya

Optimisation of supportive, palliative and end of life care ( Dr Zipporah Ali - Africa Organisation for Research & Training in Cancer, Kenya )

What is required to advance data ethics, data sharing, and Open Science across...

Dr Priya Kumari - Regional Cancer Centre Trivandrum, Trivandrum, India

What is required to advance data ethics, data sharing, and Open Science across LMICs ( Dr Priya Kumari - Regional Cancer Centre Trivandrum, Trivandrum, India )

A genomic assay may predict long-term prognosis in premenopausal patients with...

Dr Ruth O'Regan - University of Rochester, Rochester, USA

A genomic assay may predict long-term prognosis in premenopausal patients with HR+ early-stage breast cancer ( Dr Ruth O'Regan - University of Rochester, Rochester, USA )

Breast cancer in elderly patients: a clinicopathological review of a Nigerian...

Dr Funmilola Wuraola - Obafemi Awolowo University Teaching Hospital, Ilé-Ifẹ̀...

Breast cancer in elderly patients: a clinicopathological review of a Nigerian database ( Dr Funmilola Wuraola - Obafemi Awolowo University Teaching Hospital, Ilé-Ifẹ̀, Nigeria )

Trastuzumab deruxtecan shows greater OS compared to trastuzumab emtansine in...

Dr Sara Hurvitz - University of California, Los Angeles, USA

Trastuzumab deruxtecan shows greater OS compared to trastuzumab emtansine in patients with HER2 + mBC ( Dr Sara Hurvitz - University of California, Los Angeles, USA )

Adjuvant endocrine therapy +/- 1 year of everolimus fails to improve iDFS and...

Dr Mariana Chavez Mac Gregor - MD Anderson Cancer Center, Houston, USA

Adjuvant endocrine therapy +/- 1 year of everolimus fails to improve iDFS and OS in patients with high-risk HR+, HER2-negative BC ( Dr Mariana Chavez Mac Gregor - MD Anderson Cancer Center, Houston, USA )

Camizestrant may be superior to fulvestrant in patients with hormone receptor...

Dr Mafalda Oliveira - Vall d’Hebron University Hospital, Barcelona, Spain

Camizestrant may be superior to fulvestrant in patients with hormone receptor-positive, HER2-negative breast cancer ( Dr Mafalda Oliveira - Vall d’Hebron University Hospital, Barcelona, Spain )

Opinion: Premature regular approval by the FDA

Dr Bishal Gyawali - Queen's University, Kingston, Canada

Opinion: Premature regular approval by the FDA ( Dr Bishal Gyawali - Queen's University, Kingston, Canada )

Addition of platinum to standard neoadjuvant chemotherapy improves EFS in...

Dr Sudeep Gupta - Tata Memorial Centre, Mumbai, India

Addition of platinum to standard neoadjuvant chemotherapy improves EFS in patients with TNMBC ( Dr Sudeep Gupta - Tata Memorial Centre, Mumbai, India )

HER2DX confirms the ability of the test to predict long-term survival and...

Prof Aleix Prat - Hospital Clínic Barcelona, Barcelona, Spain

HER2DX confirms the ability of the test to predict long-term survival and response to anti-HER2 therapy in BC ( Prof Aleix Prat - Hospital Clínic Barcelona, Barcelona, Spain )

Treatment decision guided by CTC count may improve long-term outcomes for mBC

Prof Jean-Yves Pierga - Institut Curie, Paris, France

Treatment decision guided by CTC count may improve long-term outcomes for mBC ( Prof Jean-Yves Pierga - Institut Curie, Paris, France )

Access to Oncology Medicines Coalition - The Medicines Patent Pool

Charles Gore - Medicines Patent Pool, Geneva, Switzerland

Access to Oncology Medicines Coalition - The Medicines Patent Pool ( Charles Gore - Medicines Patent Pool, Geneva, Switzerland )

More from ecancer